Advancing Postmenopausal Preventive Therapy

NCT04103476 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

385

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerosis
Cognitive Decline

Interventions

COMBINATION_PRODUCT: Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
OTHER: Placebo

Sponsor

University of Southern California

Collaborators

[object Object]